Atlas Trials

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Clinical trial NCT06487000 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06487000
Sponsor
Enzychem Lifesciences Corporation
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Atopic Dermatitis
Start date
2025-05-01
Primary completion
2026-10-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.